BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 34780807)

  • 1. Cytochrome P450 2D (CYP2D) enzyme dysfunction associated with aging and serotonin deficiency in the brain and liver of female Dark Agouti rats.
    Haduch A; Danek PJ; Kuban W; Pukło R; Alenina N; Gołębiowska J; Popik P; Bader M; Daniel WA
    Neurochem Int; 2022 Jan; 152():105223. PubMed ID: 34780807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of ageing and cerebral serotonin deficit on the activity of cytochrome P450 2D (CYP2D) in the brain and liver of male rats.
    Haduch A; Pukło R; Alenina N; Nikiforuk A; Popik P; Bader M; Daniel WA
    Neurochem Int; 2020 Dec; 141():104884. PubMed ID: 33091481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of brain serotonin deficit (TPH2-KO) on the expression and activity of liver cytochrome P450 enzymes in aging male Dark Agouti rats.
    Haduch A; Bromek E; Kuban W; Basińska-Ziobroń A; Danek PJ; Alenina N; Bader M; Daniel WA
    Pharmacol Rep; 2023 Dec; 75(6):1522-1532. PubMed ID: 37848703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronic treatment with asenapine affects cytochrome P450 2D (CYP2D) in rat brain and liver. Pharmacological aspects.
    Danek PJ; Bromek E; Haduch A; Daniel WA
    Neurochem Int; 2021 Dec; 151():105209. PubMed ID: 34666077
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of brain cytochrome P450 (CYP2D) in the metabolism of monoaminergic neurotransmitters.
    Anna Haduch A; Bromek E; Daniel WA
    Pharmacol Rep; 2013; 65(6):1519-28. PubMed ID: 24553000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-Term Treatment with Atypical Antipsychotic Iloperidone Modulates Cytochrome P450 2D (CYP2D) Expression and Activity in the Liver and Brain via Different Mechanisms.
    Danek PJ; Daniel WA
    Cells; 2021 Dec; 10(12):. PubMed ID: 34943983
    [No Abstract]   [Full Text] [Related]  

  • 7. The activity of brain and liver cytochrome P450 2D (CYP2D) is differently affected by antidepressants in the chronic mild stress (CMS) model of depression in the rat.
    Haduch A; Rysz M; Papp M; Daniel WA
    Biochem Pharmacol; 2018 Oct; 156():398-405. PubMed ID: 30195732
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Atypical Antipsychotic Lurasidone Affects Brain but Not Liver Cytochrome P450 2D (CYP2D) Activity. A Comparison with Other Novel Neuroleptics and Significance for Drug Treatment of Schizophrenia.
    Danek PJ; Daniel WA
    Cells; 2022 Nov; 11(21):. PubMed ID: 36359909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Melatonin Supports CYP2D-Mediated Serotonin Synthesis in the Brain.
    Haduch A; Bromek E; Wójcikowski J; Gołembiowska K; Daniel WA
    Drug Metab Dispos; 2016 Mar; 44(3):445-52. PubMed ID: 26884482
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Effect of the Selective N-methyl-D-aspartate (NMDA) Receptor GluN2B Subunit Antagonist CP-101,606 on Cytochrome P450 2D (CYP2D) Expression and Activity in the Rat Liver and Brain.
    Haduch A; Bromek E; Pukło R; Jastrzębska J; Danek PJ; Daniel WA
    Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of psychotropic drugs on cytochrome P450 2D (CYP2D) in rat brain.
    Haduch A; Bromek E; Daniel WA
    Eur J Pharmacol; 2011 Jan; 651(1-3):51-8. PubMed ID: 21115002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective deficiency of debrisoquine 4-hydroxylase activity in mouse liver microsomes.
    Masubuchi Y; Iwasa T; Hosokawa S; Suzuki T; Horie T; Imaoka S; Funae Y; Narimatsu S
    J Pharmacol Exp Ther; 1997 Sep; 282(3):1435-41. PubMed ID: 9316857
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The cytochrome P450 2D-mediated formation of serotonin from 5-methoxytryptamine in the brain in vivo: a microdialysis study.
    Haduch A; Bromek E; Kot M; Kamińska K; Gołembiowska K; Daniel WA
    J Neurochem; 2015 Apr; 133(1):83-92. PubMed ID: 25581337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imipramine-induced inactivation of a cytochrome P450 2D enzyme in rat liver microsomes: in relation to covalent binding of its reactive intermediate.
    Masubuchi Y; Igarashi S; Suzuki T; Horie T; Narimatsu S
    J Pharmacol Exp Ther; 1996 Nov; 279(2):724-31. PubMed ID: 8930177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Simultaneous alterations of brain and plasma serotonin concentrations and liver cytochrome P450 in rats fed on a tryptophan-free diet.
    Kot M; Pilc A; Daniel WA
    Pharmacol Res; 2012 Oct; 66(4):292-9. PubMed ID: 22749902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The engagement of brain cytochrome P450 in the metabolism of endogenous neuroactive substrates: a possible role in mental disorders.
    Haduch A; Daniel WA
    Drug Metab Rev; 2018 Nov; 50(4):415-429. PubMed ID: 30501426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of CYP2D in rat brain in methamphetamine-induced striatal dopamine and serotonin release and behavioral sensitization.
    Stocco MR; El-Sherbeni AA; Zhao B; Novalen M; Tyndale RF
    Psychopharmacology (Berl); 2021 Jul; 238(7):1791-1804. PubMed ID: 33649968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic nicotine treatment induces rat CYP2D in the brain but not in the liver: an investigation of induction and time course.
    Yue J; Miksys S; Hoffmann E; Tyndale RF
    J Psychiatry Neurosci; 2008 Jan; 33(1):54-63. PubMed ID: 18197273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Participation of cytochrome P450-2B and -2D isozymes in the demethylenation of methylenedioxymethamphetamine enantiomers by rats.
    Kumagai Y; Lin LY; Hiratsuka A; Narimatsu S; Suzuki T; Yamada H; Oguri K; Yoshimura H; Cho AK
    Mol Pharmacol; 1994 Feb; 45(2):359-65. PubMed ID: 7906857
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regioselectivity and substrate concentration-dependency of involvement of the CYP2D subfamily in oxidative metabolism of amitriptyline and nortriptyline in rat liver microsomes.
    Masubuchi Y; Iwasa T; Fujita S; Suzuki T; Horie T; Narimatsu S
    J Pharm Pharmacol; 1996 Sep; 48(9):925-9. PubMed ID: 9036183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.